As of September 30, 2026, AbCellera Biologics, Inc. carries a market capitalization of 4.23B, placing it among publicly traded companies globally. Its enterprise value stands at 3.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.23B |
| Enterprise Value | 3.67B |
AbCellera Biologics, Inc.'s next confirmed earnings release is scheduled for February 23, 2027.
| Earnings Date | 2/23/2027 |
As of September 30, 2026, AbCellera Biologics, Inc. has 326.33M shares outstanding.
| Shares Outstanding | 326.33M |
These figures are as of September 30, 2026. The price-to-sales ratio is 66.42, and the price-to-book ratio stands at 4.51.
| PS Ratio | 66.42 |
| PB Ratio | 4.51 |
| P/TBV Ratio | 4.91 |
| P/FCF Ratio | -137.20 |
| P/OCF Ratio | -292.08 |
These figures are as of September 30, 2026. The EV/Sales ratio of 61.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.67B versus a market cap of 4.23B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 61.35 |
As of September 30, 2026, AbCellera Biologics, Inc. maintains a current ratio of 12.43, meaning it holds 12.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.60, indicating elevated leverage, while an interest coverage ratio of -4,005.19 demonstrates limited ability to service its debt obligations.
| Current Ratio | 12.43 |
| Quick Ratio | 11.80 |
| Debt / Equity | 12.60 |
| Debt / EBITDA | -0.80 |
| Interest Coverage | -4,005.19 |
Over the twelve months ended September 30, 2026, AbCellera Biologics, Inc. posted a negative return on equity (ROE) of -14.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.39, reflecting losses generated across the asset base. The company generates approximately 106,530.66 in revenue per employee across its workforce of 562.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -14.64 |
| Return on Assets (ROA) | -10.39 |
| Revenue Per Employee | 106,530.66 |
| Employee Count | 562.00 |
Over the twelve months ended September 30, 2026, AbCellera Biologics, Inc. recorded an income tax benefit of -19.87M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -150.71M and -130.84M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -19.87M |
As of the close on November 17, 2026, AbCellera Biologics, Inc.'s stock has gained approximately 226.50% over the past 52 weeks. The 50-day moving average sits at 10.95, while the 200-day moving average is 6.46.
| 52-Week Price Change | 226.50% |
| 50-Day Moving Average | 10.95 |
| 200-Day Moving Average | 6.46 |
Over the twelve months ended September 30, 2026, AbCellera Biologics, Inc. generated 59.87M in revenue and converted that into -130.84M in net income, yielding earnings per share of -0.43. EBITDA reached -148.42M, while operating income came in at -165.03M.
| Revenue | 59.87M |
| Operating Income | -165.03M |
| Pretax Income | -150.71M |
| Net Income | -130.84M |
| EBITDA | -148.42M |
| EBIT | -178.39M |
| Earnings Per Share (EPS) | -0.43 |
As of September 30, 2026, AbCellera Biologics, Inc. holds 674.45M in cash and equivalents against 118.07M in total debt, resulting in a net debt position of -144.52M. Total book value stands at 937.44M, with working capital of 710.86M providing operational flexibility.
| Cash & Cash Equivalents | 674.45M |
| Total Debt | 118.07M |
| Net Debt | -144.52M |
| Equity (Book Value) | 937.44M |
| Book Value Per Share | 2.87 |
| Working Capital | 710.86M |
AbCellera Biologics, Inc. produced -13.61M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -15.37M in capital expenditures, free cash flow totaled -28.98M - equivalent to -0.09 per share.
| Operating Cash Flow | -13.61M |
| Capital Expenditures | -15.37M |
| Free Cash Flow | -28.98M |
| FCF Per Share | -0.09 |
These figures cover the twelve months ended September 30, 2026. The operating margin of -275.65 and net profit margin of -218.54 provide insight into operational efficiency.
| Operating Margin | -275.65 |
| Pretax Margin | -251.72 |
| Profit Margin | -218.54 |
| EBITDA Margin | -247.90 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -0.73: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.55, meaning AbCellera Biologics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -4.55 |
| FCF Yield | -0.73 |
As of September 30, 2026, AbCellera Biologics, Inc. has an Altman Z-Score of 6.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.70 |
Already premium?